中证医疗

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Norges Bank Increases Holding of Tigermed to 813,800 Shares

Hangzhou Therapeutic Biotechnology Proposes Up to 100 Million Yuan Stock Repurchase Plan

Citi Group Reduced Its Holding of KaiLaiIn H Shares

CSO 实际控制 persons under investigation for disclosure violations related to shareholding changes

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Reduces Holdings in Kangbok Chemical's H Shares

BlackRock Increases Holding in Wuxi Biologics H Shares

JPMorgan Reduces Long Position in Kerry Logistics Shares

Goldman Sachs Downgrades Taige Pharma's Profit Forecast and Target Price

159849

159102

159506

512010

159837

510660

On April 14th, the General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism of Pharmaceuticals," marking the transformation of the pharmaceutical pricing mechanism and promoting high-quality development in the pharmaceutical industry. The new policy formulates differentiated policies for innovative drugs and generic drugs, supports reasonable pricing for innovative drugs, breaks the restrictions of medical insurance payment standards, and encourages enterprise innovation. The generic drug industry will face reshuffling, strengthening centralized procurement regulations, and preventing the impact of low-price bidding on supply. It is expected that small and medium-sized generic drug companies will accelerate elimination, leading to an increase in industry concentration

腾讯新闻 - 财经

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern CNI HK Connect Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Innovative Drugs ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Good news! Drug prices are no longer "one-size-fits-all": Innovative drugs can increase prices reasonably, while generic drugs will face survival of the fittest

399933

000933

512170

159303

159929

513060

560260

The General Office of the State Council has issued an opinion to improve the price formation mechanism for centralized volume-based drug procurement, promote standardization and normalization of drug procurement, and expand channels for docking between pharmaceutical enterprises and medical institutions. The opinion emphasizes demand orientation and quality priority, aiming to form reasonable prices through fair competition while optimizing procurement rules to ensure drug quality and stable supply. Additionally, it strengthens policy coordination between medical insurance payment standards and procurement prices, ensuring that payment standards for drugs within the medical insurance catalog are based on the winning bid prices

Wallstreetcn

800 Health Care

Hwabao WP CSI Medical Service ETF

Dacheng Hang Seng Health Care ETF(QDII)

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

GF Fund CSI Medical Service ETF

State Council Office: Improve the Price Formation Mechanism for Centralized Volume-Based Drug Procurement and Enhance Management of Listed Drug Prices

300医药

159839

000037

As of April 6, 112 biopharmaceutical companies in the A-share market have disclosed their annual reports, with 60 companies showing a year-on-year increase in net profit attributable to shareholders, among which 40 companies experienced growth in both revenue and net profit. Some companies have seen growth due to increased commercialization of innovative drugs and revenue from external licensing, while others are facing pressure due to strategic adjustments. Currently, the development characteristics of the pharmaceutical industry are evident, with deepening reforms on the payment side, innovative leaps on the supply side, restructuring of health service models, and diversification of consumer demand. Among the 40 companies with dual growth, 16 have seen a net profit increase of over 50%

China Universal CNI BIOMEDICINE ETF

SSE Health Care

Biomedicine Sector Performance Scan: 40 Companies with Double Growth, 29 Companies with Double Decline, Driven by "Innovation + Going Global"

159828

159847

National Committee member Ding Lieming proposed the establishment of a long-term special fund for pharmaceutical innovation to promote the development of China's innovative drug industry. He emphasized that building a comprehensive capital support system is key, including expanding industrial investment funds and facilitating channels for listings and mergers and acquisitions. Ding Lieming pointed out that although China's innovative drug market is gradually gaining international recognition, a stable policy environment and a healthy capital ecosystem are still needed to support long-term research and development

Guotai CSI Medical Service ETF

E Fund CSI Medical Service ETF

National Committee Member Ding Lieming: Proposes that the government guide funds and state-owned capital to establish a long-term special fund for pharmaceutical innovation

中证医疗(399989.SZ)

Good news! Drug prices are no longer "one-size-fits-all": Innovative drugs can increase prices reasonably, while generic drugs will face survival of the fittest

State Council Office: Improve the Price Formation Mechanism for Centralized Volume-Based Drug Procurement and Enhance Management of Listed Drug Prices

Biomedicine Sector Performance Scan: 40 Companies with Double Growth, 29 Companies with Double Decline, Driven by "Innovation + Going Global"

National Committee Member Ding Lieming: Proposes that the government guide funds and state-owned capital to establish a long-term special fund for pharmaceutical innovation